Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Chun Gong, Fei-jiao Ge, Ming Ni, Jianming Xu, Rongrui Liu, Chuanhua Zhao, Jun-Yan Gu, Yan Wang, Zhaoli Tan, Ru Jia, Mansheng Li, Shuji Ogino, He-Fei Wang, Yang Jin, Yunping Zhu, Li Lin, Youliang Wang, Yu Ling Chen, Tao Liu, Zhi Rong Qian
Publikováno v:
Clinical Cancer Research. 23:4602-4616
Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of
Autor:
Nadia Russolillo, Salvatore Siena, Enzo Medico, Michela Buscarino, Federica Di Nicolantonio, Davide Torti, Paolo Massucco, Alberto Bardelli, Alberto Pisacane, Luca Molinaro, Francesco Galimi, Andrea Bertotti, Mauro Risio, Davide Corà, Emanuele Valtorta, Giorgia Migliardi, Francesco Sassi, Claudio Isella, Lorenzo Capussotti, Paolo M. Comoglio, Andrea Muratore, Anna Sapino, Consalvo Petti, Livio Trusolino, Silvia Marsoni, Andrea Sartore-Bianchi, Marcello Gambacorta, Dario Ribero
Publikováno v:
Cancer Discovery; Vol 1
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine.
Autor:
Sander R. Piersma, Henk M.W. Verheul, Thang V. Pham, Livio Trusolino, Tim R.A. Schelfhorst, Connie R. Jimenez, Mariette Labots, Robin Beekhof, Jaco C. Knol, Andrea Bertotti, Nicole C.T. van Grieken
Publikováno v:
Cancer Research. 76:880-880
Introduction: The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has resulted in the clinical use of targeted therapies in the treatmen
Autor:
Ashley M. Kern, Patricia Greninger, Jason A. Efstathiou, Mechthild Krause, Henning Willers, Meng Wang, Dipanjan Chowdhury, Anurag K. Singh, Michael Baumann, Marieke Hülskötter, Yunfeng Pan, Jeff Settleman, Cyril H. Benes
Publikováno v:
Cancer Research. 74:LB-209
Non-small cell lung cancer (NSCLC) with mutations in the KRAS oncogene is generally resistant to targeted agents directed against the epidermal growth factor receptor (EGFR). Although EGFR is active in KRAS-mutant cancers its role in supporting cell
Autor:
Rachel Leah, Ruth Feltell, Christopher Torrance, Ramu Mangena, Annette S. Little, D P Gitterman, Holly Astley, Kyla Grimshaw, David Hughes, Jessica Hunt
Publikováno v:
Molecular Cancer Therapeutics. 12:A148-A148
Successful drug development in oncology requires a deeper understanding of the functional consequences of the diverse genetic changes observed in human cancers. For example, responses to epidermal growth factor receptor (EGFR) inhibitors are observed
Autor:
Roman K. Thomas, Juliann Chmielecki, Kazuhiko Shien, Helen Pan, Katsuyuki Kiura, Cindy L. Vnencak-Jones, Ya-Lun Lin, Hiromasa Yamamoto, Kadoaki Ohashi, Katerina Politi, James Chih-Hsin Yang, Marc Ladanyi, Lu Wang, Shinichi Toyooka, Aoe Keisuke, William Pao, Vincent A. Miller, Lynnette Fernandez, Maria E. Arcila
Publikováno v:
Cancer Research. 72:1897-1897
EGFR mutant lung cancers are highly sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), but in the metastatic setting, acquired drug resistance is inevitable. Second-site EGFR mutations, MET amplification, PIK3CA m
Autor:
Miguel Angel Molina, Clara Mayo, Carlos Camps, Enric Carcereny, Rafael Rosell, Jordi Bertran-Alamillo, Susana Benlloch, Miquel Taron, Bartomeu Massuti, Santiago Viteri
Publikováno v:
Cancer Research. 72:4596-4596
Background: Advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations has an average time to progression (TTP) of 14 months (mo) and overall survival of 27 mo when treated with erlotinib. However, EGFR mu
Autor:
Katerina Politi
Publikováno v:
Clinical Cancer Research. 18:IA4-IA4
Mutations in exons encoding the epidermal growth factor receptor (EGFR) are found in 10–15% of lung adenocarcinomas. The two most common mutations: a point mutation in exon 21 that leads to substitution of an arginine for a leucine at position 858
Autor:
Nhu-An Pham, David B. Krizman, Ming-Sound Tsao, Richard Adams, Yuhong Wei, Paul J. Taylor, Michael F. Moran, Jon Burrows, Todd Hembrough, Sheeno Thyparambil, Marlene Darfler, Bharat Jasani, Jiefei Tong
Publikováno v:
Cancer Research. 71:4919-4919
The epidermal growth factor receptor (EGFR) is a drug target for both small molecule and antibody therapeutics and has been approved in non small-cell lung carcinoma (NSCLC) and colorectal carcinoma (CRC) among other indications. These drugs block re
Autor:
Kikuya Kato, Kimiyoshi Nishitani, Masahiko Higashiyama, Ken Kodama, Jiro Okami, Kazuya Taniguchi
Publikováno v:
Cancer Research. 70:1782-1782
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib or erlotinib, are effective therapies for non-small cell lung cancer (NSCLC) patients with primary EGFR mutations. However, most patients who initially respo